608 related articles for article (PubMed ID: 18955668)
21. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
22. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
23. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension.
Umar S; Hessel M; Steendijk P; Bax W; Schutte C; Schalij M; van der Wall E; Atsma D; van der Laarse A
Pathol Res Pract; 2007; 203(12):863-72. PubMed ID: 17913382
[TBL] [Abstract][Full Text] [Related]
24. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
25. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
26. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis.
Kobayashi H; Yasuda S; Bao N; Iwasa M; Kawamura I; Yamada Y; Yamaki T; Sumi S; Ushikoshi H; Nishigaki K; Takemura G; Fujiwara T; Fujiwara H; Minatoguchi S
J Cardiovasc Pharmacol; 2009 Dec; 54(6):510-9. PubMed ID: 19755919
[TBL] [Abstract][Full Text] [Related]
27. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
28. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
29. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
31. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Kojonazarov B; Sydykov A; Pullamsetti SS; Luitel H; Dahal BK; Kosanovic D; Tian X; Majewski M; Baumann C; Evans S; Phillips P; Fairman D; Davie N; Wayman C; Kilty I; Weissmann N; Grimminger F; Seeger W; Ghofrani HA; Schermuly RT
Int J Cardiol; 2013 Sep; 167(6):2630-7. PubMed ID: 22854298
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
[TBL] [Abstract][Full Text] [Related]
33. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
Schellings MW; Baumann M; van Leeuwen RE; Duisters RF; Janssen SH; Schroen B; Peutz-Kootstra CJ; Heymans S; Pinto YM
Hypertension; 2006 Mar; 47(3):467-74. PubMed ID: 16432052
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
35. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Plastaras JP; Kim SH; Liu YY; Dicker DT; Dorsey JF; McDonough J; Cerniglia G; Rajendran RR; Gupta A; Rustgi AK; Diehl JA; Smith CD; Flaherty KT; El-Deiry WS
Cancer Res; 2007 Oct; 67(19):9443-54. PubMed ID: 17909054
[TBL] [Abstract][Full Text] [Related]
36. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
37. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
38. Emerging therapies for the treatment of pulmonary hypertension.
Stenmark KR; Rabinovitch M
Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S85-90. PubMed ID: 20216170
[TBL] [Abstract][Full Text] [Related]
39. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
[TBL] [Abstract][Full Text] [Related]
40. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]